Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2019

View Archived Issues

Sanofi begins phase I study of SAR-442085 in relapsed or refractory multiple myeloma

New phase I study investigates V-941 with KRAS-mutant solid tumors

New yellow fever therapeutic targets identified

Blood regulatory T cells mirror those in breast tumors

Stem cells don't need glutamine

Results presented from phase II ZEBRA study of pembrolizumab, the largest study in SBA to date

Preliminary data presented for patients with CRC enrolled in the phase I GATTO study

TAS-118 plus oxaliplatin improves survival compared to S-1 plus cisplatin in patients with AGC

Advaxis presents new immune data from ongoing ADXS-NEO phase I study

Activity maintained for recombinant factor VIII modified to extend half-life: MG-1121

AVROBIO announces first kidney biopsy results and additional data for AVR-RD-01

FLVCR1 predicts poor outcome in esophageal squamous cell carcinoma

Inscopix and Biogen announce research collaboration targeting chronic pain

NSI-189 shows promise in murine models of Alzheimer's disease

New public-private partnership to support phase III trial of Janssen's mosaic-based HIV vaccine

Sosei and Genentech enter GPCR-focused research collaboration and license agreement

Arbutus reports preliminary phase Ia/Ib data on oral HBV capsid inhibitor AB-506

Synlogic reports topline data from phase I/IIa study of SYNB-1618 in patients with PKU

Chengdu Huajian Future Technology patents IDO1 inhibitors

NIAID grant supports development of Kineta's LHF-535 for hemorrhagic arenaviruses

Janssen Pharmaceutica identifies menin/MLL interaction inhibitors

IDO1 inhibitors presented by Shanghai De Novo Pharmatech

Alkermes plans to expand planned ALKS-3831 schizophrenia NDA to include bipolar I disorder

MedImmune describes KEAP1/NRF2 interaction inhibitors

3M Pharmaceuticals patents new vaccine adjuvants

SurgiMab initiates phase III trial of SGM-101 in patients undergoing surgery for colorectal cancer